MCID: SPC001
MIFTS: 26

Space Motion Sickness

Categories: Ear diseases

Aliases & Classifications for Space Motion Sickness

MalaCards integrated aliases for Space Motion Sickness:

Name: Space Motion Sickness 12 44 15 17 70

Classifications:



External Ids:

Disease Ontology 12 DOID:4796
MeSH 44 D018489
SNOMED-CT 67 21162009
UMLS 70 C0242700

Summaries for Space Motion Sickness

MalaCards based summary : Space Motion Sickness is related to motion sickness and pathologic nystagmus. An important gene associated with Space Motion Sickness is AVP (Arginine Vasopressin). The drugs Diphenhydramine and Histamine have been mentioned in the context of this disorder. Affiliated tissues include eye, hypothalamus and amygdala.

Related Diseases for Space Motion Sickness

Diseases related to Space Motion Sickness via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 13)
# Related Disease Score Top Affiliating Genes
1 motion sickness 30.9 HRH1 FOS EFHD2
2 pathologic nystagmus 10.2
3 paralytic ileus 10.1 MLN AVP
4 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 10.0
5 pica disease 10.0
6 muscular atrophy 10.0
7 ileus 10.0
8 tremor 10.0
9 functional gastric disease 9.8 PPY MLN
10 diabetic autonomic neuropathy 9.7 PPY MLN
11 autonomic neuropathy 9.7 PPY MLN
12 hematuria, benign familial 9.6 HRH1 FOS
13 diamond-blackfan anemia 5 9.6 PPY FOS

Graphical network of the top 20 diseases related to Space Motion Sickness:



Diseases related to Space Motion Sickness

Symptoms & Phenotypes for Space Motion Sickness

Drugs & Therapeutics for Space Motion Sickness

Drugs for Space Motion Sickness (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 14)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Diphenhydramine Approved, Investigational Phase 4 147-24-0, 58-73-1 3100
2
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
3
Promethazine Approved, Investigational Phase 4 60-87-7 4927
4 Gastrointestinal Agents Phase 4
5 Hypnotics and Sedatives Phase 4
6 Anesthetics Phase 4
7 Antiemetics Phase 4
8 Anesthetics, Local Phase 4
9 Histamine Antagonists Phase 4
10 Dermatologic Agents Phase 4
11 Neurotransmitter Agents Phase 4
12
Histamine Phosphate Phase 4 51-74-1 65513
13 Histamine H1 Antagonists Phase 4
14 Anti-Allergic Agents Phase 4

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Countermeasures to Reduce Sensorimotor Impairment and Space Motion Sickness Resulting From Altered Gravity Levels Completed NCT02136420 Phase 4 Promethazine;Placebo

Search NIH Clinical Center for Space Motion Sickness

Cochrane evidence based reviews: space motion sickness

Genetic Tests for Space Motion Sickness

Anatomical Context for Space Motion Sickness

MalaCards organs/tissues related to Space Motion Sickness:

40
Eye, Hypothalamus, Amygdala

Publications for Space Motion Sickness

Articles related to Space Motion Sickness:

(show top 50) (show all 219)
# Title Authors PMID Year
1
Space motion sickness: A common neurovestibular dysfunction in microgravity. 61
31134912 2019
2
Alterations of Functional Brain Connectivity After Long-Duration Spaceflight as Revealed by fMRI. 61
31333476 2019
3
A Case Study of Severe Space Motion Sickness. 61
30020061 2018
4
Drugs in space: Pharmacokinetics and pharmacodynamics in astronauts. 61
28533143 2017
5
Orientation Preferences and Motion Sickness Induced in a Virtual Reality Environment. 61
28923138 2017
6
Subjective Vertical Conflict Theory and Space Motion Sickness. 61
26802378 2016
7
Restricted sedation and absence of cognitive impairments after administration of intranasal scopolamine. 61
26268532 2015
8
Microgravity Simulated by the 6° Head-Down Tilt Bed Rest Test Increases Intestinal Motility but Fails to Induce Gastrointestinal Symptoms of Space Motion Sickness. 61
26055239 2015
9
Intranasal scopolamine affects the semicircular canals centrally and peripherally. 61
25953832 2015
10
Quantitative orientation preference and susceptibility to space motion sickness simulated in a virtual reality environment. 61
25647233 2015
11
Dose escalation pharmacokinetics of intranasal scopolamine gel formulation. 61
25187210 2015
12
Binocular misalignments elicited by altered gravity provide evidence for nonlinear central compensation. 61
26082691 2015
13
Effects of sex and gender on adaptation to space: neurosensory systems. 61
25401941 2014
14
Motion sickness: more than nausea and vomiting. 61
24961738 2014
15
Space motion sickness countermeasures: a pharmacological double-blind, placebo-controlled study. 61
24919385 2014
16
Women's health in spaceflight. 61
24919386 2014
17
Distance and Size Perception in Astronauts during Long-Duration Spaceflight. 61
25369884 2013
18
Space motion sickness and motion sickness: symptoms and etiology. 61
23855067 2013
19
Exercise equipment used in microgravity: challenges and opportunities. 61
22580492 2012
20
Training complexity is not decisive factor for improving adaptation to visual sensory conflict. 61
23366702 2012
21
Pharmaceutical countermeasures have opposite effects on the utricles and semicircular canals in man. 61
22517315 2012
22
A rationale for space motion sickness. 61
21748915 2011
23
Weight loss in humans in space. 61
21702312 2011
24
A rationale for space motion sickness. 61
21485406 2011
25
A re-investigation of the role of utricular asymmetries in Space Motion Sickness. 61
21558639 2011
26
Effects of promethazine and midodrine on orthostatic tolerance. 61
21235099 2011
27
[Physiological changes in microgravity]. 61
20669641 2009
28
Cardio-postural deconditioning: A model for post-flight orthostatic intolerance. 61
19379846 2009
29
Space headache: a new secondary headache. 61
19175610 2009
30
Adaptation to motion sickness from torso rotation affects symptoms from supine head nodding. 61
17760283 2007
31
Microcapsule-gel formulation of promethazine HCl for controlled nasal delivery: a motion sickness medication. 61
17454422 2007
32
Space motion sickness. 61
17021896 2006
33
Space motion sickness: incidence, etiology, and countermeasures. 61
16935570 2006
34
Motion sickness provoked by torso rotation predicts that caused by head nodding. 61
16964739 2006
35
Influence of simulated weightlessness on the intramuscular and oral pharmacokinetics of promethazine in 12 human volunteers. 61
16920895 2006
36
Touch down: the effect of artificial touch cues on orientation in microgravity. 61
16806701 2006
37
Stroboscopic vision as a treatment for motion sickness: strobe lighting vs. shutter glasses. 61
16422446 2006
38
The influence of weightlessness on pharmacokinetics. 61
16313274 2005
39
Preflight virtual reality training as a countermeasure for space motion sickness and disorientation. 61
15828634 2005
40
The effects of vestibular stimuli on brain cognitive processing: an ERP study. 61
15597048 2004
41
Effects of drug countermeasures for space motion sickness on working memory in humans. 61
15451046 2004
42
Stimulation of the semicircular canals via the rotary chair as a means to test pharmacologic countermeasures for space motion sickness. 61
15354005 2004
43
Physiological, pharmacokinetic, and pharmacodynamic changes in space. 61
15286087 2004
44
Size and cell number of the utricle in kinetotically swimming fish: a parabolic aircraft flight study. 61
15880898 2004
45
Histology of the utricle in kinetotically swimming fish: a parabolic aircraft flight study. 61
14977072 2004
46
Gene expression in autonomic areas of the medulla and the central nucleus of the amygdala in rats during and after space flight. 61
14960339 2004
47
[Study on space motion sickness before, during and after spaceflight]. 61
14753243 2003
48
Vestibular suppression during space flight. 61
15096678 2003
49
Neurovestibular symptoms following space flight. 61
14757912 2003
50
Neurophysiology of developing fish at altered gravity: background--facts--perspectives. 61
14631633 2003

Variations for Space Motion Sickness

Expression for Space Motion Sickness

Search GEO for disease gene expression data for Space Motion Sickness.

Pathways for Space Motion Sickness

GO Terms for Space Motion Sickness

Biological processes related to Space Motion Sickness according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor signaling pathway GO:0007186 9.46 PPY MLN HRH1 AVP
2 response to organic cyclic compound GO:0014070 9.32 FOS AVP
3 transforming growth factor beta receptor signaling pathway GO:0007179 9.26 WFIKKN2 FOS
4 negative regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043154 8.96 VIL1 AVP
5 positive regulation of vasoconstriction GO:0045907 8.62 HRH1 AVP

Molecular functions related to Space Motion Sickness according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuropeptide hormone activity GO:0005184 9.16 PPY AVP
2 cysteine-type endopeptidase inhibitor activity involved in apoptotic process GO:0043027 8.96 VIL1 AVP
3 hormone activity GO:0005179 8.8 PPY MLN AVP

Sources for Space Motion Sickness

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....